Skip to main content

Table 3 Side effects in each treatment group.

From: Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection

 

QT

OAR

Total patients

35 (64%) *

20 (44%) *

Dyspepsia

  

+

17

8

+++

1

1

Taste-sensation alteration

  

+

12

5

+++

2

 

Dizziness

  

+

13

4

+++

1

 

Diarrhoea

  

+

10

6

+++

1

 

Nausea/Vomiting

  

+

10

5

+++

3

1

Loss of appetite

  

+

9

6

+++

2

 

Cephalea

  

+

8

6

+++

1

1

Odynophagia

  

+

4 (2 candidiasis)

 

+++

  

Asthenia/tiredness

  

+

2

3

+++

  

Total episodes

85

43

Total episodes +++

11

3

  1. * p 0.042
  2. +: : mild/moderate
  3. +++: : severe